Clinical trials: Cyclophosphamide, completed
Testicular Neoplasms
High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II
High-dose chemotherapy (HD-CT) is able to circumvent platinum-resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach.
- Trial name
- NCT00231582
- Testing
- epirubicin, high-dose and autologous stem cell transplantation, paclitaxel
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in…
- Trial name
- NCT02027935
- Testing
- Aldesleukin, Autologous CD8+ Melanoma Specific T Cells, Cyclophosphamide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and…
- Conditions
- CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
- Trial name
- NCT01994850
- Testing
- brentuximab vedotin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma (Skin)
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells.
- Trial name
- NCT00002535
- Testing
- aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Sponsor
- St. Luke's Medical Center
Breast Cancer
Docetaxel in Node Positive Adjuvant Breast Cancer
The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable…
- Trial name
- TAX316 (NCT00688740)
- Testing
- Docetaxel, 5-fluorouracil, Doxorubicin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 1,491 people
- Sponsor
- Sanofi
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005092
- Testing
- Cyclophosphamide, Psoralen, Thiotepa
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Fibrillary Glomerulonephritis
Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
This study aims to evaluate the clinical and histological effects of two rituximab-based regimens in fibrillary glomerulonephritis.
- Trial name
- CD20FG (NCT06680349)
- Testing
- Anti-CD20 antibodies
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Turin, Italy
Advanced Ovarian Cancer, Malignant Melanoma
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
This is a phase 1b study for patients with metastatic (cancer has spread to various parts of the body) melanoma and ovarian cancer.
- Trial name
- ACTIVATE (NCT03158935)
- Testing
- Cyclophosphamide, Fludarabine, Pembrolizumab
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00379015
- Testing
- trastuzumab, cyclophosphamide, docetaxel
- Where
- 5 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of interleukin-2 with that of observation following radiation therapy, combination chemotherapy, and peripheral stem cell transplantation in treating patients who have…
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00002649
- Testing
- aldesleukin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- National Cancer Institute (NCI)
Behcet's Syndrome
Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.
- Trial name
- NCT00664599
- Testing
- Rituximab, Cytotoxic Combination
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Tehran University of Medical Sciences
Breast Cancer, Fever
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
- Conditions
- Breast Cancer, Fever, Neutropenia
- Trial name
- NCT00115414
- Testing
- pegfilgrastim, docetaxel, doxorubicin
- Sponsor
- Amgen
Prostatic Neoplasms
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
- Trial name
- NCT05022849
- Testing
- JNJ-75229414, Bridging Therapy
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia.
- Conditions
- Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00061945
- Testing
- allopurinol, cyclophosphamide, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- National Cancer Institute (NCI)
NY-ESO-1-expressing Tumors
CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors
Subjects will receive immunizations every other week for 8 immunizations prior to clinical and immunological evaluations. Patients will then receive immunizations every month up to one year.
- Trial name
- NCT00819806
- Testing
- Vaccine only, Vaccine + cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hassane M. Zarour, MD
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Background: The immune system fights infection and can affect cancer cells. T cells are white blood cells that are a major part of the immune system. T cells can destroy tumors.
- Trial name
- NCT02659943
- Testing
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib)…
- Trial name
- IFM2013-04 (NCT01971658)
- Testing
- Thalidomide®, Cyclophosphamide, Velcade®
- Where
- 62 sites in France
- Volunteers
- 358 people
- Sponsor
- Nantes University Hospital
Hematologic Neoplasm, HIV Infection
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
This study will investigate the safety and effectiveness of a new stem cell transplant procedure to treat acute or chronic leukemia, multiple myeloma, myelodysplastic syndrome, Hodgkin's and non-Hodgkin's lymphoma in HIV-infected…
- Trial name
- NCT00005785
- Testing
- GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Retinoblastoma, Clear Cell Sarcoma
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded…
- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor
- Trial name
- AflacST1402 (NCT02390843)
- Testing
- Simvastatin, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve…
- Trial name
- PEONY (NCT02586025)
- Testing
- FEC Chemotherapy, Surgery, Docetaxel
- Where
- 23 sites in China, South Korea and 2 more
- Volunteers
- 329 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.